Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma

OBJECTIVES: Tyrosine kinase inhibitors (TKIs) are the primary therapeutic option for patients with advanced-stage epidermal growth factor receptor-mutant (EGFR-m) lung adenocarcinoma. However, the role of EGFR-TKIs in advanced-stage lung cancer is uncertain regardless of therapeutic methods. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ying-Yi, Lin, Kuan-Hsun, Kuo, Yen-Shou, Tsai, Yuan-Ming, Huang, Hsu-Kai, Huang, Tsai-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571456/
https://www.ncbi.nlm.nih.gov/pubmed/37833769
http://dx.doi.org/10.1186/s12957-023-03203-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571456/
https://www.ncbi.nlm.nih.gov/pubmed/37833769
http://dx.doi.org/10.1186/s12957-023-03203-6

Ejemplares similares